Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: https://qrco.de/bgXpKn ---------- Sponsor: MuseCell Innovations MuseCell Innovations is a science-backed regenerative medicine company developing patented Dezawa MuseCells®, unique stem cells that support the body's natural repair and regeneration processes. Benefits include cellular renewal, tissue repair, healthy aging, improved resilience, and overall wellbeing. Click the link below to explore the science, research, and technology behind this innovative approach to regenerative medicine. Link: musecellinnovations.com ---------- Guests: Dominik Duscher MD PhD President & Chief Executive Officer at MuseCell Innovations Instagram: www.instagram.com/dr.dominikduscher/ Website: musecellinnovations.com Dr. Jeffrey J. Wiegers Chief Medical Officer at MuseCell Innovations Instagram: www.instagram.com/jeffwiegers Website: musecellinnovations.com ---------- What if a naturally occurring stem cell subpopulation could home to sites of injury and support tissue repair across multiple indications? Phil Newman and Dr. Nina Patrick sit down with Dr. Dominik Duscher, MD PhD, President and CEO of MuseCell Innovations, and Dr. Jeffrey Wiegers, MD, Chief Medical Officer, to explore the unique properties of Dezawa MuseCells®. In this session, they describe these cells as highly enriched in a purified product with pluripotent-like potential, signaling that enables targeted homing, and immune tolerance that supports allogeneic use without major immune activation, based on early human experience. From first-in-human intravenous use in acute myocardial infarction showing safety and encouraging left ventricle performance signals, to randomized placebo-controlled subacute ischemic stroke data showing higher response rates than placebo, they walk through human trial experience without overstating effects. They also discuss repeated intravenous dosing in an amyotrophic lateral sclerosis study suggesting stabilizing signal with minimal adverse events, single-arm spinal cord injury data, and early work in neonatal hypoxic-ischemic encephalopathy showing recovery signals in some infants. They also address broader practicalities around manufacturing rigor, quality control, and provider competency as determinants of safety in clinical settings, and they describe the need for clear documentation and oversight to avoid unlicensed or inferior products. In this episode, you’ll learn: Why pluripotency, homing ability, and immune tolerance are considered key features of Dezawa MuseCells® and how these properties may relate to tissue repair. What early human studies in conditions like heart attack, stroke, ALS, spinal cord injury, and neonatal brain injury have shown in terms of safety and early clinical signals.Why manufacturing quality, purification, and standardization are critical for consistency and safety in cell-based therapies.Why clinician expertise and proper oversight matter when these therapies move from research into clinical use. How to think about verifying product authenticity and avoiding unregulated or non-standard cell therapies. If you want to understand the biological features, emerging human data, and practical considerations around Dezawa MuseCells® as discussed by leaders in the field, this episode connects cellular biology with real-world context for regenerative medicine and longevity. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
